|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Trial implications for diabetes management and the impact of the new ADA/EASD consensus statement treatment algorithm were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners.
|
30857522 |
2019 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The overall prevalence of undiagnosed diabetes was 9.8% (1059/10794) according to ADA criteria.
|
30115607 |
2018 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
According to the ADA criteria of HbA1c cut-off point (5.7%), 3,517 subjects with NGT screened from a total of 7,855 middle-aged and elderly Chinese without known diabetes were divided into two groups, 1,877 subjects with HbA1c < 5.7% and 1,640 with HbA1c ≥ 5.7% (i.e. iHH).
|
28904260 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
In 2010, the ADA made the recommendation to include hemoglobin A1c (HbA1c) as a diagnostic test for diabetes, in addition to the oral glucose tolerance test or fasting plasma glucose.
|
29868987 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients aged 45-75 years within 2 years of first fulfilling the ADA criteria for diabetes will be prospectively enrolled in this study.
|
29192743 |
2018 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum ADA activities were significantly higher in cases compared with controls (p<0.001) showing significant positive correlation (p<0.05) with FBS, PPBS, HbA1c, and alcoholism; while no correlation was found with age, sex, ethnicity, BMI, waist-hip ratio, dietary habits, smoking, and duration of diabetes.
|
28321313 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
ADA = American Diabetes Association CRP = C-reactive protein DD = definite diabetes FPG = fasting plasma glucose HbA1c = glycosylated hemoglobin MENA = Middle-East North Africa ND = no diabetes PD = probable diabetes RD = at risk of diabetes T2D = type 2 diabetes mellitus TSH = thyroid-stimulating hormone.
|
28683240 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
We compared prediabetes definitions based on fasting glucose concentration (American Diabetes Association [ADA] fasting glucose concentration cutoff 5·6-6·9 mmol/L and WHO fasting glucose concentration cutoff 6·1-6·9 mmol/L), HbA<sub>1c</sub> (ADA HbA<sub>1c</sub> cutoff 5·7-6·4% [39-46 mmol/mol] and International Expert Committee [IEC] HbA<sub>1c</sub> cutoff 6·0-6·4% [42-46 mmol/mol]), and 2 h glucose concentration (ADA and WHO 2 h glucose concentration cutoff 7·8-11·0 mmol/L).
|
27863979 |
2017 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Four researchers manually reviewed all records and classified patients according to their diabetic status (diabetic: diabetes registered as a health problem or fulfilling the ADA criteria; non-diabetic: not fulfilling the ADA criteria and having at least one fasting glycemia below 126 mg/dL; inconclusive: no data regarding their diabetic status or only one abnormal value).
|
29054261 |
2017 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with diabetes: ADA*01;*01 (142/159, 89.3%), ADA*01;*02 (16/159, 10.1%) and ADA*02;*02 (1/159, 0.6%); control group: ADA*01;*01 (146/160, 91.3%), ADA*01;*02 (12/160, 7.5%) and ADA*02;*02 (2/160, 1.3%); patients at risk of cardiovascular disease: ADA*01;*01 (71/78, 91.0%), ADA*01;*02 (7/78, 9.0%) and ADA*02;*02 (0/78, 0.0%).
|
24836059 |
2014 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Revision of the ADA-classification of diabetes mellitus type 2 (DMT2): the importance of maturity onset diabetes (MOD), and senile diabetes (DS).
|
20800300 |
2011 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
The association of ACP1 and ADA1 with CAD depends on sex and diabetes.
|
20581655 |
2010 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ketosis-prone atypical diabetes that has been classified by ADA as idiopathic Type 1 diabetes or Type 1b is the most common atypical form.
|
11938022 |
2002 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess, by a house to house study, the prevalence of diabetes, impaired glucose tolerance (IGT) and their associated risk factors in Benghazi, Libya using 75 gram oral glucose tolerance test (OGTT) and ADA 1997 and WHO 1998 diagnostic criteria.
|
11852372 |
2001 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Digging the genome for diabetes mellitus: the 2nd ADA Research Symposium on the Genetics of Diabetes, San Jose, CA, USA, 17-19 October 1999.
|
11228869 |
2001 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
These patients (2 out of 141) that cannot be classified as Type 1a diabetic patients lack clinical characteristics of Type 1b diabetes and have to be reconsidered for a more appropriate ADA classification.
|
10707033 |
2000 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
According to ADA criteria, 588 (74.6%) women were normal, 46 (5.8%) had impaired fasting glucose, 82 (10.4%) had impaired glucose tolerance, 29 (3.7%) had both impaired fasting glucose and impaired glucose tolerance, and 43 (5.4%) had diabetes.
|
10388966 |
1999 |
|
Diabetes
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A further single large pedigree with MODY has shown linkage to a marker for the adenosine deaminase gene (ADA, chromosome 20q), although the diabetes susceptibility gene at this locus has not been identified.
|
7705022 |
1994 |